专利检索 ap:("Dong-eok Lee" OR "Myung-suk Oh" OR "Ki-wan Kim" OR "Bo-sup Chung" OR "Ji-sook Park") AND inv:"Ki-wan Kim" 第 1 页

1.

发明授权
Fusion protein having enhanced in vivo erythropoietin activity 有权

公开(公告)号：US07091326B2

公开(公告)日：2006-08-15

申请号：US10196183

申请日：2002-07-17

申请人： Dong-eok Lee , Myung-suk Oh , Ki-wan Kim , Bo-sup Chung , Ji-sook Park

发明人： Dong-eok Lee , Myung-suk Oh , Ki-wan Kim , Bo-sup Chung , Ji-sook Park

IPC分类号： C07K14/59 , C07K14/505 , C12N15/00 , C12N15/62

CPC分类号： C12N15/62 , A61K38/00 , C07K14/505 , C07K14/59 , C07K2319/00 , C07K2319/75

摘要： Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.